Nisa Investment Advisors LLC increased its position in Accolade, Inc. (NASDAQ:ACCD – Get Rating) by 4,861.5% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 25,800 shares of the company’s stock after acquiring an additional 25,280 shares during the period. Nisa Investment Advisors LLC’s holdings in Accolade were worth $453,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Accolade by 50.9% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,370 shares of the company’s stock worth $115,000 after acquiring an additional 1,474 shares during the period. First Bank & Trust increased its holdings in shares of Accolade by 104.9% in the 4th quarter. First Bank & Trust now owns 8,256 shares of the company’s stock worth $218,000 after acquiring an additional 4,226 shares during the period. Arizona State Retirement System increased its holdings in shares of Accolade by 11.3% in the 4th quarter. Arizona State Retirement System now owns 9,781 shares of the company’s stock worth $258,000 after acquiring an additional 991 shares during the period. Clarius Group LLC acquired a new stake in shares of Accolade in the 4th quarter worth about $279,000. Finally, ProShare Advisors LLC increased its holdings in shares of Accolade by 70.3% in the 4th quarter. ProShare Advisors LLC now owns 10,996 shares of the company’s stock worth $289,000 after acquiring an additional 4,541 shares during the period. Institutional investors and hedge funds own 81.43% of the company’s stock.
Accolade Stock Performance
ACCD stock opened at $9.52 on Tuesday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 3.95 and a current ratio of 3.95. The stock has a market cap of $677.91 million, a P/E ratio of -1.56 and a beta of 2.17. The firm has a 50 day simple moving average of $7.51 and a 200 day simple moving average of $12.73. Accolade, Inc. has a 52 week low of $4.61 and a 52 week high of $49.47.
Analyst Upgrades and Downgrades
ACCD has been the topic of several research analyst reports. Berenberg Bank reissued a “buy” rating and set a $11.00 target price on shares of Accolade in a research note on Friday, July 1st. Credit Suisse Group cut shares of Accolade from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $33.00 to $9.00 in a research note on Friday, April 29th. The Goldman Sachs Group lowered their target price on shares of Accolade from $15.00 to $13.00 and set a “buy” rating on the stock in a research note on Friday, July 1st. Needham & Company LLC lowered their target price on shares of Accolade from $33.00 to $12.00 in a research note on Friday, April 29th. Finally, Stifel Nicolaus reduced their price objective on shares of Accolade to $16.00 in a research report on Friday, April 29th. Seven equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.00.
Accolade, Inc, together with its subsidiaries, develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists.
- Get a free copy of the StockNews.com research report on Accolade (ACCD)
- Taking a Look at Nvidia’s Stock Amidst The Semiconductor Chip Gut
- Palantir Stock is Showing Signs of Life
- The Institutions Like The Color Of PPG Industries
- What Investors Need to Know to Beat the Market
- Alcoa Is Well-Positioned For 2022 and 2023
Receive News & Ratings for Accolade Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accolade and related companies with MarketBeat.com's FREE daily email newsletter.